Analyst Sees Abbott Undervaluation, Flags Recall Costs and China Slowdown as Temporary
ABT•Analyst argues that Abbott’s current 18x forward P/E undervalues a projected mid-single-digit revenue CAGR through 2028 driven by diagnostics and diabetes care, while $200 million in device recall costs and a 10% China sales drop are temporary. Trading below the healthcare sector’s 21x average P/E suggests mispricing relative to the company’s earnings growth runway.
1. Valuation Overview
The analyst highlights that Abbott currently trades at an 18x forward P/E, below the healthcare sector average of 21x. This discount is viewed as a mispricing given the company’s ability to deliver mid-single-digit revenue growth over the next three years.
2. Near-Term Noise
Recent headwinds include approximately $200 million in charges from a medical device recall and a 10% year-over-year decline in China sales. These factors have weighed on margins but are expected to normalize as operational improvements and pricing actions take effect.
3. Growth Outlook
Secular drivers in diagnostics, including expanding immunoassay platforms, and diabetes care innovations such as next-generation insulin pumps are projected to fuel revenue growth. The analyst forecasts these segments to deliver the bulk of mid-single-digit CAGR through 2028, offsetting short-term volatility.
